No genetic effect of alpha1-antichymotrypsin in Alzheimer disease.
Alzheimer disease (AD) is the most common neurodegenerative disorder for individuals over the age of 40. AD has a complex etiology, and it is likely that multiple genes, acting independently and/or interacting, affect the risk of developing AD. Several genes involved with AD have been described already, but only the APOE gene on chromosome 19q has been shown to affect the risk of the common late onset form of AD. alpha1-Antichymotrypsin (AACT) is a major component of the amyloid plaques found in the brains of AD patients, and an allele in its gene has been proposed to increase the risk of developing AD when also associated with the APOE-4 allele. We have examined the role of this AACT polymorphism in a large set of families and sporadic cases, and do not see any effect, either alone or in combination with the APOE-4 allele.
Haines
J L
JL
Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, Massachusetts, 02129, USA.
Pritchard
M L
ML
Saunders
A M
AM
Schildkraut
J M
JM
Growdon
J H
JH
Gaskell
P C
PC
Farrer
L A
LA
Auerbach
S A
SA
Gusella
J F
JF
Locke
P A
PA
Rosi
B L
BL
Yamaoka
L
L
Small
G W
GW
Conneally
P M
PM
Roses
A D
AD
Pericak-Vance
M A
MA
D000544:Alzheimer Disease / Q000201:enzymology / Q000235:genetics*; D001057:Apolipoproteins E / Q000235:genetics; D005787:Gene Frequency; D008040:Genetic Linkage; D006801:Humans; D016017:Odds Ratio; D012044:Regression Analysis; D000514:alpha 1-Antichymotrypsin / Q000235:genetics*
D001057:Apolipoproteins E; D000514:alpha 1-Antichymotrypsin